
SVA
Healthcare · Biotechnology · $642.4M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jul 31, 2024
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2026 | Before the open | — | — | — |
| Aug 16, 2024 | Time not confirmed | -0.03 | -0.11 | -266.7% |
| Jul 13, 2022 | Time not confirmed | — | 0.00 | — |
| Apr 29, 2022 | Time not confirmed | — | 29.44 | — |
| Nov 29, 2021 | Time not confirmed | — | 0.00 | — |
| Aug 24, 2021 | Time not confirmed | — | 44.78 | — |
| May 5, 2021 | Time not confirmed | — | 0.68 | — |
| Nov 12, 2020 | Time not confirmed | — | 0.08 | — |
| Aug 28, 2020 | Time not confirmed | — | -0.05 | — |
| Apr 30, 2020 | Time not confirmed | — | 0.14 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.07 | — |
| Nov 15, 2019 | Time not confirmed | — | 0.06 | — |
| Jul 10, 2019 | Time not confirmed | — | 0.01 | — |
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus;…
| Jun 30, 2019 |
| Time not confirmed |
| 0.00 |
| 0.11 |
| — |
| Feb 27, 2019 | Time not confirmed | — | 0.11 | — |
| Nov 15, 2018 | Time not confirmed | — | 0.12 | — |
| Aug 15, 2018 | Time not confirmed | — | 0.24 | — |
| May 11, 2018 | Time not confirmed | — | 0.26 | — |
| Mar 31, 2018 | Time not confirmed | 0.00 | 0.14 | — |